Cerity Partners LLC Trims Position in DaVita Inc. (NYSE:DVA)

Key Points

• Cerity Partners LLC significantly reduced its stake in DaVita Inc. by 69.1%, holding 2,466 shares valued at $377,000 after selling 5,502 shares in the first quarter.
• DaVita Inc. reported earnings of $2.00 per share, surpassing expectations, with revenues of $3.22 billion, indicating a 5.0% year-over-year growth.
• Major institutional investors have adjusted their positions, with 90.12% of DaVita's stock owned by institutional investors after numerous changes in holdings during the previous quarter.

Cerity Partners LLC trimmed its position in DaVita Inc. (NYSE:DVA - Free Report) by 69.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,466 shares of the company's stock after selling 5,502 shares during the period. Cerity Partners LLC's holdings in DaVita were worth $377,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Sei Investments Co. boosted its holdings in shares of DaVita by 212.6% in the fourth quarter. Sei Investments Co. now owns 90,769 shares of the company's stock worth $13,578,000 after buying an additional 61,731 shares during the last quarter. UniSuper Management Pty Ltd raised its position in DaVita by 21.8% in the fourth quarter. UniSuper Management Pty Ltd now owns 11,506 shares of the company's stock worth $1,721,000 after acquiring an additional 2,063 shares during the period. Norges Bank purchased a new position in shares of DaVita during the 4th quarter worth $7,297,000. New Age Alpha Advisors LLC bought a new stake in shares of DaVita during the 4th quarter valued at $1,782,000. Finally, denkapparat Operations GmbH purchased a new stake in shares of DaVita in the 4th quarter worth $263,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Performance

Shares of NYSE DVA opened at $145.03 on Friday. The stock has a market cap of $10.95 billion, a PE ratio of 14.37, a price-to-earnings-growth ratio of 1.00 and a beta of 1.11. DaVita Inc. has a 1 year low of $131.76 and a 1 year high of $179.60. The firm has a fifty day moving average price of $140.31 and a 200-day moving average price of $148.33. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.25. The company had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. DaVita's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.26 EPS. Equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DVA has been the topic of a number of recent research reports. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial reduced their price target on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $167.40.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.